New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

In a patient with cardiac light chain amyloid who has significant heart failure symptoms, including inotrope dependence at presentation, how much clinical benefit does treatment provide?

2
1 Answers

Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic Rochester

In patients with cardiac light chain (AL) amyloidosis who present with significant heart failure symptoms and inotrope dependence, the clinical benefit of treatment is a complex and nuanced issue. This scenario often reflects an extreme end of the disease spectrum. Historically, patients with advanc...

Is there a role for anti-fibrinolytic agents in patients with hyperfibrinolytic disseminated intravascular coagulation?

1 Answers

Mednet MemberInvited Expert
Hematology · Mayo Clinic

DIC is a complex clinicopathologic syndrome. There are no randomized trials to support evidence-based practice. The following principles apply: 1) antifibrinolytics should not be used in patients with organ failure or those that are asymptomatic. One could justify their use in this group of patients...

Is there specific data on using luspatercept for sickle beta+ thalassemia with transfusion-dependent anemia?

3 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Weill Cornell Medical College

The mechanism of action of luspatercept is to trap and remove ligands of the TGF beta superfamily of ligands, specifically the growth and development factors (GDFs) 11 nd 15. This allows more maturation and differentiation of the erythroid precursors, and an increase in red cell production and relea...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

What factors drive your selection between tafasitamab and epcoritamab for a patient with relapsed/refractory follicular lymphoma?

4 Answers

Mednet MemberInvited Expert
Medical Oncology · Lewisburg Cancer Center | Evangelical Hospital

For an older patient or a patient with comorbidities, if one is prioritizing outpatient simplicity, tafasitamab + R² delivers an NCCN category 1 benefit with substantially lower acute immune toxicity. If CD19 CAR-T is the next planned therapy, however, the CD19-targeting overlap is a consideration t...

What is the treatment strategy and priority in a patient with newly diagnosed Hodgkin lymphoma but HLH at presentation?

1 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · University of Toronto

Would be good to have more details about the patient's medical condition and organ function. How definitive is the HLH diagnosis as against Hodgkin's with B symptoms? Malignancy-associated HLH at diagnosis is due to cytokines/chemokines produced by the tumor cells, so the major part of the therapy i...

For cancer patients with suspected PE, how should the HYDRA trial--which proposes using the YEARS algorithm is as safe as a CTPA-only approach--change the diagnostic workup?

1
1 Answers

Mednet MemberInvited Expert
Hematology · Medical University of South Carolina

The YEARS algorithm was originally developed to determine which adults with suspected pulmonary embolism (PE) can safely avoid computed tomographic pulmonary angiography (CTPA). It uses three criteria — clinical signs of deep-vein thrombosis, hemoptysis, and PE judged the most likely diagnosis — com...

Should platelet transfusions be considered for anti-platelet agent reversal in patients with major bleeding?

1
2 Answers

Mednet MemberInvited Expert
Medical Oncology · Ohio State University

Patients on plavix and/or aspirin are at risk for bleeding whether in relation to surgery or bleeding from the gi tract. Much like the management of patients on anticoagulation temporary reversal of antiplatelet drugs is only achieved by normalizing platelet function. This is the same principle used...

If blood counts are being checked during concurrent chemoradiation, is there a number at which point you would recommend a radiation treatment break?

1
3 Answers

Mednet MemberInvited Expert
Radiation Oncology · Rutgers Cancer Institute of New Jersey

I’ll let the platelets go as low as 10K before stopping. I lean heavily on the rate of decline to intervene with a break sooner than the absolute numbers if heading for trouble and later if decline is slow and at reaching the end of treatment.

For pregnant nontransfusion dependent beta thalassemia patients, when would you consider ESAs for worsening anemia?

1 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Weill Cornell Medical College

Non-transfusion-dependent thalassemia (NTDT) patients tend to have elevated erythropoietin (EPO) levels already, proportionate to their degree of anemia. The basic pathophysiology of thalassemia is ineffective erythropoiesis (IE), in which proliferation, in response to high EPO levels, is already su...

What could explain failure to luspatercept in patients with transfusion-dependent beta thalassemia?

1 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Weill Cornell Medical College

Luspatercept works by trapping TGF beta ligands (GDF 11 and 15) and optimizing maturation and differentiation of erythroid precursors, thus facilitating increased output of red cells.In individuals who have beta zero-beta zero thalassemia, this must mean that the cells coming out would contain hemog...